Ritleng®+ is FCI’s latest autostable bicanalicular nasolacrimal intubation indicated for epiphora, canalicular pathologies, congenital lacrimal duct obstruction and dacryocystorhinostomy (DCR).
Ritleng®+ is FCI’s latest autostable bicanalicular nasolacrimal intubation indicated for epiphora, canalicular pathologies, congenital lacrimal duct obstruction and dacryocystorhinostomy (DCR).
FCI Ophthalmics
[email protected]
Phone : 800-932-4202
Fax : 781-826-9060